SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.85-4.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (9113)9/11/2003 5:30:01 PM
From: keokalani'nui  Read Replies (1) of 52153
 
>>I get weary of bio execs talking about great trial designs and strong endpoints as the trial is in progress. Then the results come in and suddenly there were problems with the trial parameters that kept the wonder drug from hitting the primary endpoint<<

Worth repeating.

--The Weary

I've got one that has NEVER hit a primary endpoint and still might end up on the fda's desk. Naturally, it's for CV disease, or autoimmune disease or cancer or graft rejection or......It's a broad spectrum placebo you see.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News